Artigos
UTILIZAÇÃO DO TOCILIZUMAB NO TRATAMENTO DA COVID-19
- Saiba mais...
Os antagonistas da interleucina-6 (IL-6), como o tocilizumab, o sarilumab e o siltuximab, entre outros, indicados no tratamento de doenças reumatológicas, têm vindo a ser utilizados no tratamento da COVID-19, uma vez que a infeção pelo vírus SARS-CoV-2 induz a produção de citocinas pró-inflamatórias, incluindo IL-6. Os antagonistas da IL-6 têm sido utilizados no pressuposto de que as suas propriedades imunossupressoras, com redução dos níveis ou dos efeitos da IL-6, poderiam controlar a disfunção imunitária e a inflamação, e reduzir a duração e/ou a gravidade da COVID-19.
O tocilizumab tem sido o antagonista IL-6 mais investigado. Existe alguma evidência, proveniente de revisões sistemáticas e de ensaios clínicos, de que a sua utilização em casos graves de COVID-19 possa estar associada a menor risco de mortalidade ou de ventilação mecânica, o que conduziu à sua inclusão nalgumas normas de tratamento. A evidência para os outros antagonistas IL-6 é ainda escassa ou inexistente.
LEITURA RECOMENDADA
The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab for the Treatment of COVID-19. Last Updated: March 5, 2021
https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/
https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/
COVID-19 rapid evidence summary: Tocilizumab for COVID-19. National Institute for Health and Care Excellence. Published: 15 January 2021
https://www.nice.org.uk/advice/es33/resources/covid19-rapid-evidence-summary-tocilizumab-for-covid19-pdf-1158234594757
https://www.nice.org.uk/advice/es33/resources/covid19-rapid-evidence-summary-tocilizumab-for-covid19-pdf-1158234594757
Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 Mar 18;3:CD013881. doi: 10.1002/14651858.CD013881.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881/epdf/full
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881/epdf/full
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, Jenkins G. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Feb 12: thoraxjnl-2020-215266. doi: 10.1136/thoraxjnl-2020-215266.
https://thorax.bmj.com/content/thoraxjnl/early/2021/02/15/thoraxjnl-2020-215266.full.pdf
https://thorax.bmj.com/content/thoraxjnl/early/2021/02/15/thoraxjnl-2020-215266.full.pdf
Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, Altannir Y, Al-Tannir M, Tleyjeh R, Hassett L, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5. PMID: 33161150; PMCID: PMC7644182.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644182/pdf/main.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644182/pdf/main.pdf
REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Feb 25:NEJMoa2100433. doi: 10.1056/NEJMoa2100433. Epub ahead of print. PMID: 33631065; PMCID: PMC7953461.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953461/pdf/NEJMoa2100433.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953461/pdf/NEJMoa2100433.pdf
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMoa2028700.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028700?articleTools=true
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028700?articleTools=true
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781101/pdf/NEJMoa2030340.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781101/pdf/NEJMoa2030340.pdf
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646626/pdf/NEJMoa2028836.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646626/pdf/NEJMoa2028836.pdf
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187
Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186